The impact of antiangiogenic therapy combined with Transarterial Chemoembolization on enhancement based quantitative tumor response assessment in patients with hepatocellular carcinoma
Susanne Smolka(Yale University), Jean-François H. Geschwind(Johns Hopkins University), Yanhong Deng(Sun Yat-sen University), Wilfred Manzano(University of California, Irvine), Eric J. Reiner(Ministry of the Environment, Conservation and Parks), Julius Chapiro(Yale University), Yan Zhao(Zhengzhou University), James S. Duncan(Yale University), John Treilhard(Yale University), Bernhard Gebauer(Charité - Universitätsmedizin Berlin), MingDe Lin(Yale University), Bernd Hamm(European Society of Radiology)
Cited by 7
Related Papers
Tumor glycolysis as a target for cancer therapy: progress and prospects
|Molecular Cancer|2013|1.5k
Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
|European Journal of Cancer|2011|615
Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA
|Clinical Cancer Research|2018|456